We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Portal Launched to Accelerate and Improve Biomedical Research Funding

By LabMedica International staff writers
Posted on 03 Apr 2016
A new website launched in collaboration with the National Institutes of Health (NIH) will provide new funding opportunities for scientific projects and present an alternative option to the traditional government grant mechanisms.

In an effort to further scientific advancement, NIH and Leidos (Reston, VA, USA), a health, national security and engineering solutions company, now provide the portal OnPAR – Online Partnership to Accelerate Research. More...
OnPAR represents a new funding paradigm that provides a second opportunity for promising unfunded NIH research proposals. Leidos developed the OnPAR processes and website and will manage the overall program.

There is currently a surplus of high-quality biomedical research applications that merit funding through alternative sources. Through the OnPAR public-private partnership, exceptional applications that were not originally funded by NIH will be matched for potential funding with a participating organization's specialized area of interest.

"OnPAR presents another avenue to fund important biomedical research," said Jim Pannucci, Leidos Director, Life Sciences, "The program will revolutionize the scientific funding environment and foster more discoveries at a faster pace to benefit and improve global health."

Research projects will be considered and funded by OnPAR funding organization members based on their specific research priority areas and requirements. For the pilot project, funding organization members include: Adenoid Cystic Carcinoma Research Foundation, Breast Cancer Research Foundation, Children's Tumor Foundation, JDRF, Melanoma Research Alliance, National Alopecia Areata Foundation, and Parent Project Muscular Distropy. These foundations were selected to span different disease areas and varied foundation sizes.

As the program progresses, OnPAR plans to increase its membership to include additional foundations, pharmaceutical companies, and other life sciences funding organizations across varied disease areas. Leidos also foresees expanding the program globally.

Related Links:

Leidos



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.